Treatment of skeletal disorders
CA 2262269 C · Owner: Ke, Hua Zhu · Inventors: Steppan, Claire Monica; Swick, Andrew Gordon; Ke, Hua Zhu
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is a pharmaceutical composition for treating bone loss in a mammal comprising a therapeutically effective amount of leptin or a leptin mimetic. Also disclosed is a pharmaceutical composition for treating bone fracture enhancing, bone healing following facial reconstruction maxillary, reconstruction or madibular reconstruction enhancing long bone, extension, enhancing the healing rate of a bone graft enhancing, prosthetic growth and inducing vertebral. synostosis comprising, a therapeutically effective amount of leptin or a leptin mimetic. Still further disclosed is a pharmaceutical composition comprising leptin or a leptin mimetic and estrogen a selective, estrogen receptor …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 19, 1999 and granted July 15, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 19, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 19, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.